|Mr. Alex Karlsson-Parra||Co-Founder & Chief Scientific Officer||1.42M||N/A||1950|
|Dr. Erik Manting Ph.D.||Chief Exec. Officer||N/A||N/A||1971|
|Ms. Lotta Ferm||Interim Chief Financial Officer||N/A||N/A||1966|
|Mr. Sijme Zeilemaker||Head of Investor Relations & Corp. Communication||N/A||N/A||1987|
|Ms. Sharon Longhurst||Head of CMC||N/A||N/A||1969|
|Dr. Sven M. Rohmann M.D., MBA, Ph.D.||Bus. Devel. Advisor||N/A||N/A||1962|
|Dr. Jeroen Rovers||Chief Medical Officer||N/A||N/A||1971|
|Mr. Per-Olof Gunnesson||Advisor Contracts||N/A||N/A||1945|
Immunicum AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trial for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as has completed Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I ALISON clinical trial for the treatment of ovarian cancers. It has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study; and research collaboration with Icahn School of Medicine At Mount Sinai. The company is headquartered in Stockholm, Sweden.
Immunicum AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.